Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L

Published byΩκεανός Βαμβακάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L"— Presentation transcript:

1 Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small- Cell Lung Cancer 
Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L. Parker, PhD, MBA  Journal of Thoracic Oncology  Volume 9, Issue 2, Pages (February 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Clinical trial success rates for stage IIIb–IV NSCLC drug-development compounds being tested in various treatment indications are displayed along with industry-wide clinical trial success rate expectations. Transition probability refers to the probability of a compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Clinical trial success rates for stage IIIb–IV NSCLC biomarker targeted and nonbiomarker targeted therapy are displayed along with industry-wide clinical trial success rate expectations. The figure displays parallel analyses for success rates of small-molecule compounds and success rates across all compound types. Transition probability refers to the probability of a compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Clinical trial success rates for stage IIIb–IV NSCLC drug development are displayed along with industry-wide clinical trial success rate expectations for both small-molecule and biologic drugs. Transition probability refers to the probability of a compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Clinical trial success rates for stage IIIb–IV non– small-cell lung cancer drug-development compounds classified by mechanism of action are displayed along with industry-wide clinical trial success rate expectations. Transition probability refers to the probability of a compound successfully transitioning from phase I to phase II, phase II to phase III, or phase III to Food and Drug Administration approval. The number above each bar in a clinical trial phase represents the total number of compounds that completed that clinical trial phase and does not include compounds in current active testing in that phase. Cumulative pass rates represent the product of transition probabilities across all three clinical phases and are the values shown above each bar in this section. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Clinical trial costs for each phase are displayed for each treatment indication. The number above each bar represents the cost in millions of USD for each treatment indication clinical trial phase. The total cost of clinical drug development was obtained by adding the costs of all three clinical trial phases together. NSCLC, non–small-cell lung cancer; USD, U.S. dollars. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L"

Similar presentations

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Similar presentations

Ads by Google